A cost-effectiveness analysis of first-line toripalimab plus chemotherapy in advanced nonsquamous non-small cell lung cancer in China
Sign Up to like & getrecommendations! Published in 2023 at "Expert Review of Clinical Pharmacology"
DOI: 10.1080/17512433.2023.2188194
Abstract: ABSTRACT Background This study compares first-line toripalimab with chemotherapy for advanced nonsquamous non-small cell lung cancer (NSCLC) from the perspective of the Chinese healthcare system. Research design and methods A three-state Markov model was established… read more here.
Keywords: advanced nonsquamous; toripalimab; line toripalimab; first line ... See more keywords
Efficacy and safety of toripalimab with anlotinib and chemotherapy as first-line therapy in patients with extensive-stage small-cell lung cancer: Preliminary results of an open-label, single-arm, phase II study.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.e20570
Abstract: e20570 Background: Although the combination of PD-1/PD-L1 immune checkpoint inhibitors (ICIs) with platinum-etoposide chemotherapy (EP) is the preferred first-line treatment for patients with extensive-stage small-cell lung cancer (ES-SCLC), the survival benefit of the addition of… read more here.
Keywords: toripalimab; extensive stage; treatment; safety ... See more keywords
Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III Neotorch study.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2023.41.36_suppl.425126
Abstract: 425126 Background: Adjuvant and neoadjuvant immunotherapy have been approved by US FDA to treat early-stage NSCLC. However, the optimal neoadjuvant and adjuvant treatment, including duration of treatment, are unknown. We present the interim results of… read more here.
Keywords: toripalimab; chemotherapy; stage iii; placebo ... See more keywords
Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.22.00727
Abstract: PURPOSE The CHOICE-01 study investigated the efficacy and safety of toripalimab in combination with chemotherapy as a first-line treatment for advanced non–small-cell lung cancer (NSCLC). PATIENTS AND METHODS Patients (N = 465) with treatment-naive, advanced… read more here.
Keywords: treatment naive; toripalimab; arm; naive advanced ... See more keywords
Severe cumulative skin toxicity during toripalimab combined with vemurafenib following toripalimab alone
Sign Up to like & getrecommendations! Published in 2023 at "Open Life Sciences"
DOI: 10.1515/biol-2022-0606
Abstract: Targeted therapy and PD - 1/L1 inhibitors are the main treat - ments for BRAF V600 - mutated melanomas [ 1,2 ] . Recently, PD - 1 inhibitors for melanoma with toripalimab have been developed… read more here.
Keywords: vemurafenib following; toripalimab combined; toripalimab; skin toxicity ... See more keywords
Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2021.730666
Abstract: Toripalimab (Tuoyi™) is a selective, recombinant, humanized monoclonal antibody against programmed death protein 1 (PD-1) developed by Shanghai Junshi Bioscience Co., Ltd. Toripalimab is able to bind to PD-1 and block the interaction with its… read more here.
Keywords: anti tumor; toripalimab; china; line ... See more keywords
Effectiveness and Safety of Toripalimab Combination Therapies for Patients With Chemo-Resistant Choriocarcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.815917
Abstract: Toripalimab as a novel PD-1 inhibitor has presented its promising efficacy in patients who developed chemo-refractory carcinomas, whereas no study has ever investigated the effectiveness of toripalimab in chemo-resistant choriocarcinoma. Here we reported the effectiveness… read more here.
Keywords: resistant choriocarcinoma; safety; toripalimab; patients chemo ... See more keywords